Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects.

MLA

Song, Ivy, et al. “Dolutegravir Does Not Affect Methadone Pharmacokinetics in Opioid-Dependent, HIV-Seronegative Subjects.” Drug and Alcohol Dependence, vol. 133, no. 2, Dec. 2013, pp. 781–84. EBSCOhost, https://doi.org/10.1016/j.drugalcdep.2013.08.009.

APA

Song, I., Mark, S., Chen, S., Savina, P., Wajima, T., Peppercorn, A., Bala, U., Geoffroy, P., & Piscitelli, S. (2013). Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects. Drug and Alcohol Dependence, 133(2), 781–784. https://doi.org/10.1016/j.drugalcdep.2013.08.009

Chicago

Song, Ivy, Stephen Mark, Shuguang Chen, Paul Savina, Toshihiro Wajima, Amanda Peppercorn, Urmilla Bala, Pierre Geoffroy, and Stephen Piscitelli. 2013. “Dolutegravir Does Not Affect Methadone Pharmacokinetics in Opioid-Dependent, HIV-Seronegative Subjects.” Drug and Alcohol Dependence 133 (2): 781–84. doi:10.1016/j.drugalcdep.2013.08.009.